Efficacy of vedolizumab in fistulising Crohn’s disease: Exploratory analyses of data from GEMINI 2.

Efficacy of vedolizumab in fistulising Crohn’s disease: Exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018 Feb 17;: Authors: Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K Abstract Background and Aims: Medical management of fistulising Crohn’s disease (CD) is constrained by the limited number of available therapies. We evaluated the efficacy of vedolizumab, a gut-selective α4β7 integrin antagonist approved for treating moderately to severely active CD, in a subpopulation of patients with fistulising CD who participated in the GEMINI 2 trial (NCT00783692).…

Read More

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience.

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501 Authors: Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ Abstract Background: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn’s disease (CD) therapy. Methods: Patients with CD were prospectively evaluated in this large, observational registry. Results: Patients (n = 6273) participated in this observational registry from July 1999 through March 2012; 3440 (54.8%) received infliximab (20,971…

Read More

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):465-466 Authors: Katsanos KH, Papamichael K, Cheifetz AS, Christodoulou DK PMID: 29462402 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29462402?dopt=Abstract

Read More

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):601-606 Authors: Fiorino G, Ruiz-Argüello MB, Maguregui A, Nagore D, Correale C, Radice S, Gilardi D, Allocca M, Furfaro F, Martínez A, Danese S Abstract Background: Infliximab (IFX) biosimilars CT-P13 and SB2 have comparable efficacy, safety, and immunogenicity to the originator Remicade (RMC). However, concerns about cross-switching patients between the 3 brands were raised in the absence of cross reactivity data between them. We aimed…

Read More

Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis.

Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. Inflamm Bowel Dis. 2018 Feb 15;24(3):651-659 Authors: Shah SC, Naymagon S, Panchal HJ, Sands BE, Cohen BL, Dubinsky MC Abstract Background: Standard outpatient induction dosing of infliximab (IFX) may not be effective in hospitalized ulcerative colitis (UC) patients with higher inflammatory burden and colectomy risk. Our aim was to determine whether initial IFX induction dose affects 30-day colectomy rate and other disease-related outcomes. Methods: IFX-naive hospitalized UC patients receiving at least 1 inpatient 5 mg/kg…

Read More

The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn’s Disease.

The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn’s Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):502-509 Authors: Yamada A, Komaki Y, Patel N, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A Abstract Background: Clinical and endoscopic recurrence are common after surgery in Crohn’s disease (CD). Vedolizumab has been increasingly used to treat CD, however, its effectiveness in preventing postoperative recurrence remains unknown. We aimed to investigate the use of vedolizumab in the postoperative setting and…

Read More

Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.

Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Feb 12;: Authors: Barré A, Colombel JF, Ungaro R Abstract BACKGROUND: Increased knowledge of pathways involved in the pathogenesis of IBD has led to the development of new treatment options for Crohn’s disease (CD) and ulcerative colitis (UC). Two new biological agents have been recently approved for IBD: vedolizumab and ustekinumab. They have different therapeutic targets (α4 β7 integrin for vedolizumab and interleukin-12/23 pathways for ustekinumab) than the primary biological class, anti-tumour necrosis…

Read More

Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn’s disease : a randomised controlled trial.

Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn’s disease : a randomised controlled trial. Gut. 2018 Feb 02;: Authors: Levine A, Kori M, Kierkus J, Sigall Boneh R, Sladek M, Escher JC, Wine E, Yerushalmi B, Amil Dias J, Shaoul R, Veereman Wauters G, Boaz M, Abitbol G, Bousvaros A, Turner D Abstract OBJECTIVE: Crohn’s disease (CD) pathogenesis associated with dysbiosis and presence of pathobionts in the lumen, intracellular compartments and epithelial biofilms. Azithromycin is active in all three compartments. Our…

Read More
<< Go Back